All In Biotech

Drug Trial Radar · NCT03172208

Caplacizumab Single and Multiple Dose Study in Healthy Japanese and White Subjects.

A Phase I Single Center, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Caplacizumab in Japanese and White Healthy Volunteers.

Last checked: Nov 20, 2026Latest source record: Nov 14, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

60

Actual

Start

Jun 5, 2017

Primary completion

Oct 19, 2017

Study completion Oct 19, 2017

Sponsor

Lead sponsor
Ablynx, a Sanofi companyIndustry
Sponsor type
Industry
First posted
Jun 1, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Primary objective: To assess the safety and tolerability of single ascending intravenous (i.v.) doses, a single subcutaneous (s.c.) dose of caplacizumab (Part I), and multiple s.c. doses of caplacizumab (Part II) in Japanese subjects. Secondary objectives: * To compare the pharmacokinetic (PK) and pharmacodynamic (PD) profiles (total vWF:Ag concentration levels \[vWF:Ag\], coagulation factor VIII \[FVIII:C\], and ristocetin cofactor activity \[RICO\]) after single i.v. or s.c. administration of caplacizumab in Japanese and White subjects. * To evaluate the immunogenicity of caplacizumab (anti-drug antibodies \[ADA\]) in Japanese subjects.

Conditions

  • Healthy Volunteers

Interventions

  • Caplacizumab Dose 1 iv (single-dose)Biological

    Single intravenous (iv) administration of Caplacizumab Dose 1

  • Caplacizumab Dose 2 iv (single-dose)Biological

    Single intravenous (iv) administration of Caplacizumab Dose 2

  • Caplacizumab Dose 2 sc (single-dose)Biological

    Single subcutaneous (sc) administration of Caplacizumab Dose 2

  • Caplacizumab Dose 2 sc (multiple-dose)Biological

    Once daily subcutaneous (sc) administration of Caplacizumab Dose 2 during 7 consecutive days

  • Placebo iv (single-dose)Other

    Single intravenous (iv) administration of Placebo

  • Placebo sc (single-dose)Other

    Single subcutaneous (sc) administration of Placebo

  • Placebo sc (multiple-dose)Other

    Once daily subcutaneous (sc) administration of Placebo during 7 consecutive days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The number of treatment-emergent adverse events (Safety and Tolerability)Time frame: From signing of informed consent form until Day 28 (single-dose part) or Day 34 (multiple dose part)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Investigator Site

    Glendale, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.